Trend in Traditional Medicine Research as an Alternative Treatment for Lung Cancer: Bibliometric Analysis 2015-2024
Abstract
Lung cancer, a leading cause of death, is influenced by smoking. Treatment includes conventional and alternative therapies, with traditional medicine showing potential in overcoming resistance and improving patient prognosis. This study explored the trends and developments in research related to traditional medicine as an alternative therapy for lung cancer through bibliometric analysis during the period 2015–2024. Data were obtained from the Scopus database, resulting in 349 relevant documents. Analysis using VOSviewer and R Studio software showed a significant increase in the number of publications, with a peak in 2024. This article identified contributions from 1,839 authors and 177 sources, with the Journal of Ethnopharmacology as the main contributor. Keywords such as "lung cancer," "apoptosis" and "anticancer" were frequently used, reflecting the research focus on the molecular mechanisms and potential of traditional medicine. China and India dominated the global contributions, followed by the United States. International collaboration also played an important role in the development of research. The results showed that traditional medicine, including traditional Chinese medicine (TCM) and active compounds from spices such as curcumin, have the potential to inhibit cancer cell proliferation, enhance apoptosis and overcome drug resistance. This study underscores the importance of a multidisciplinary approach to exploring traditional medicine in lung cancer therapy.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. doi: 10.3322/caac.21834.
Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Cited: 11-Jun-2024]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482357/.
Hirsch FR, Scagliotti G V., Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. The Lancet. 2017;389:299–311. doi: 10.1016/S0140-6736(16)30958-8.
Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biom Prev. 2019;28:1563–79. doi: 10.1158/1055-9965.EPI-19-0221.
Johann DJ, Steliga M, Shin IJ, Yoon D, Arnaoutakis K, Hutchins L, et al. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp Biol Med. 2018;243:262–71. doi: 10.1177/1535370217750087.
Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7. doi:10.1098/rsob.170070.
Vicidomini G. Current challenges and future advances in lung cancer: genetics, instrumental diagnosis and treatment. Cancers (Basel). 2023;15. doi:10.3390/cancers15143710.
McCulloch M, Broffman M, Van Der Laan M, Hubbard A, Kushi L, Kramer A, et al. Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: Ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther. 2011;10:260–79. doi: 10.1177/1534735411406439.
Xu LL, Zhang SF, Wang YL, Luo Y Bin, Fang ZH, Fang Y, et al. The efficacy of long-term chinese herbal medicine use on lung cancer survival time: a retrospective two-center cohort study with propensity score matching. Evid Based Complement Alternat Med. 2021 Aug 23;2021:5522934. doi: 10.1155/2021/5522934.
Wathoni N, Puluhulawa LE, Joni IM, Muchtaridi M, Mohammed AFA, Elamin KM, et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer. Drug Deliv. 2022 Dec;29(1):2959-70. doi: 10.1080/10717544.2022.2120566.
Qureshi R. Personalized drug-response prediction model for lung cancer patients using machine learning Personalized drug-response prediction model for lung cancer Personalized drug-response prediction model for lung cancer patients using machine learning patients using machine learning. TechRxiv 2020. doi: 10.36227/techrxiv.13273319.v1.
Xia L, Liu Y, Wang Y. PD-1/PD-L1 Blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24:S31–S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
Lim SM, Hong MH, Kim HR. Immunotherapy for non-small cell lung cancer: Current landscape and future perspectives. Immune Netw. 2020;20. doi: 10.4110/in.2020.20.e10.
Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891.
Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18:767–77. foi: 10.1038/s41568-018-0076-6.
Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P, et al. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A. 2015;112:E6496–E6505. doi: 10.1073/pnas.1519556112.
Huang J, Li JX, Ma LR, Xu DH, Wang P, Li LQ, et al. Traditional herbal medicine: a potential therapeutic approach for adjuvant treatment of non-small cell lung cancer in the future. Integr Cancer Ther. 2022;21. doi: 10.1177/15347354221144312.
Yu N, Xiong Y, Wang C. Bu-Zhong-Yi-Qi decoction, the water extract of Chinese traditional herbal medicine, enhances cisplatin cytotoxicity in A549/DDP cells through induction of apoptosis and autophagy. Biomed Res. Int 2017;2017. doi: 10.1155/2017/3692797.
Xiong F, Jiang M, Chen M, Wang X, Zhang S, Zhou J, et al. Study on inhibitory effect of MaiMenDong decoction and WeiJing decoction combination with cisplatin on NCI-A549 Xenograft in nude mice and its mechanism. J Cancer. 2017; 8: 2449–55. doi: 10.7150/jca.17720.
Hu Y, Li X, Lin L, Liang S, Yan J. Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis. Oncol Rep 2018; 39:1731–8. doi: 10.3892/or.2018.6234.
Zhang YN, Wu ZC, Yu HY, Wang HX, Liu G, Wang SJ, et al. Chinese herbal medicine Wenxia Changfu Formula reverses cell adhesion-mediated drug resistance via the Integrin β1-PI3K-AKT pathway in lung cancer. J Cancer. 2019;10:293–304. doi: 10.7150/jca.25163.
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417. doi: 10.1038/s41571-020-0341-y.
De Sousa Monteiro L, Bastos KX, Barbosa-Filho JM, De Athayde-Filho PF, De Fátima Formiga Melo Diniz M, Sobral MV. Medicinal plants and other living organisms with antitumor potential against lung cancer. Evid Based Complement Alternat Med. 2014;2014. doi: 10.1155/2014/604152.
Zhang W, Tian W, Wang Y, Jin X, Guo H, Wang Y, et al. Explore the mechanism and substance basis of Mahuang FuziXixin Decoction for the treatment of lung cancer based on network pharmacology and molecular docking. Comput Biol Med. 2022;151. doi: 10.1016/j.compbiomed.2022.106293.
Wang XJ, Zhou RJ, Zhang N, Jing Z. 20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy. Eur J Pharmacol. 2019;850:141–9. doi: 10.1016/j.ejphar.2019.02.023.
Lewis KM, Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Fridley C, et al. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 2015;90:182–90. doi: 10.1016/j.lungcan.2015.09.014.
Zheng J, Son DJ, Gu SM, Woo JR, Ham YW, Lee HP, et al. Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway. Sci Rep. 2016;6. doi:10.1038/srep26357.
Wang J, Chen X, Yuan M. Bibliometric analysis of traditional Chinese medicine in the treatment of inflammatory bowel disease. Allergol Immunopathol (Madr). 2024;52:31–41. doi: 10.15586/aei.v52i3.1047.
Zhang G, Qin Y, Liu S, Chen X, Zhang W. Bibliometric analysis of research trends and topic areas in traditional Chinese medicine therapy for lymphoma. Pharm Biol. 2023;62:13–21. doi: 10.1080/13880209.2023.2288697.
Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res. 2021;133:285–96. doi: 10.1016/j.jbusres.2021.04.070.
Solikhah S, Perwitasari DA, Irham LM, Matahari R. Social support in quality of life among breast cancer patients after diagnosis: a bibliometric analysis. Siriraj Med J. 2023;75:529–38. doi: 10.1080/13880209.2023.2288697.
Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. 2022; 7. doi:10.1038/s41392-022-01251-0.
Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: History, present situation, and development. Thorac Cancer. 2015;6:561–9. doi: 10.1111/1759-7714.12270.
Zhang Y, Lou Y, Wang J, Yu C, Shen W. Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment. Front Immunol. 2021;11. doi:10.3389/fimmu.2020.609705.
Zheng J, Zhou Y, Li Y, Xu DP, Li S, Li H Bin. Spices for prevention and treatment of cancers. Nutrients. 2016;8. doi:10.3390/nu8080495.
Wu L, Guo L, Liang Y, Liu X, Jiang L, Wang L. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol Rep 2015;34:3311–3317. doi: 10.3892/or.2015.4279.
Lelli D, Sahebkar A, Johnston TP, Pedone C. Curcumin use in pulmonary diseases: State of the art and future perspectives. Pharmacol Res. 2017;115:133–48. doi: 10.1016/j.phrs.2016.11.017.
Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as anticancer agents. Nutrients. 2020;12. doi:10.3390/nu12020457.
Banik K, Ranaware AM, Deshpande V, Nalawade SP, Padmavathi G, Bordoloi D, et al. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019;144:192–209. doi: 10.1016/j.phrs.2019.04.004.
Memarzia A, Saadat S, Asgharzadeh F, Behrouz S, Folkerts G, Boskabady MH. Therapeutic effects of medicinal plants and their constituents on lung cancer, in vitro, in vivo and clinical evidence. J Cell Mol Med. 2023;27:2841–63. doi: 10.1111/jcmm.17936.
Shen F, Ge C, Yuan P. Aloe-emodin induces autophagy and apoptotic cell death in non-small cell lung cancer cells via Akt/mTOR and MAPK signaling. Eur J Pharmacol 2020;886. doi: 10.1016/j.ejphar.2020.173550.
Hu X, Geetha RV, Surapaneni KM, Veeraraghavan VP, Chinnathambi A, Alahmadi TA, et al. Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino mice. Saudi J Biol Sci. 2021;28:7125–33. doi: 10.1016/j.sjbs.2021.08.001.
Magesh V, Durgabhavani K, Senthilnathan P, Rajendran P, Sakthisekaran D. In vivo protective effect of crocetin on benzo(a)pyrene-induced lung cancer in Swiss albino mice. Phytother Res 2009;23:533–9. doi: 10.1002/ptr.2666.
Rodenak-Kladniew B, Castro MA, Crespo R, Galle M, García de Bravo M. Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells. Heliyon 2020;6. doi:10.1016/j.heliyon.2020.e05639.
Zuo HL, Lin YC, Huang HY, Wang X, Tang Y, Hu YJ, et al. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective. Acta Pharmacol Sin. 2021 Jun;42(6):845-7. doi: 10.1038/s41401-021-00645-0.
Meng Z, Liu X, Wu J, Zhou W, Wang K, Jing Z, et al. Mechanisms of compound Kushen injection for the treatment of lung cancer based on network pharmacology. Evid Based Complement Alternat Med. 2019 May 28;2019:4637839. doi: 10.1155/2019/4637839.
Zhang DH, Zhang X, Peng B, Deng SQ, Wang YF, Yang L, et al. Network pharmacology suggests biochemical rationale for treating COVID-19 symptoms with a Traditional Chinese Medicine. Commun Biol. 2020 Aug 18;3(1):466. doi: 10.1038/s42003-020-01190-y.
Noor F, Tahir Ul Qamar M, Ashfaq UA, Albutti A, Alwashmi ASS, Aljasir MA. Network Pharmacology Approach for Medicinal Plants: Review and assessment. Pharmaceuticals (Basel). 2022 May 4;15(5):572. doi: 10.3390/ph15050572.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).